Y Intercept Hong Kong Ltd Buys 61,916 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Y Intercept Hong Kong Ltd raised its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 319.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 81,302 shares of the company's stock after buying an additional 61,916 shares during the period. Y Intercept Hong Kong Ltd owned 0.10% of Syndax Pharmaceuticals worth $1,565,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SNDX. Northwestern Mutual Wealth Management Co. acquired a new position in Syndax Pharmaceuticals in the second quarter valued at about $27,000. Values First Advisors Inc. acquired a new position in shares of Syndax Pharmaceuticals during the third quarter worth approximately $30,000. nVerses Capital LLC acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth approximately $33,000. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals during the third quarter worth approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock worth $58,000 after purchasing an additional 541 shares in the last quarter.

Syndax Pharmaceuticals Stock Performance

NASDAQ:SNDX traded down $0.71 during trading hours on Wednesday, hitting $14.23. The stock had a trading volume of 2,123,770 shares, compared to its average volume of 1,192,129. Syndax Pharmaceuticals, Inc. has a one year low of $14.20 and a one year high of $25.34. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -3.92 and a beta of 0.86. The business's 50 day moving average is $18.01 and its 200-day moving average is $19.55.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period in the previous year, the company posted ($0.73) EPS. On average, sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Barclays upped their target price on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an "overweight" rating in a research report on Thursday, August 15th. The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Citigroup upped their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, November 19th. Bank of America upped their target price on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday, August 15th. Finally, Stifel Nicolaus increased their price objective on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a "buy" rating in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.64.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).